---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-085865"
form_type: "8-K"
ticker: "IRWD"
cik: "0001446847"
company_name: "IRONWOOD PHARMACEUTICALS INC"
filed_at: "2022-08-04T23:59:59+00:00"
generated_at: "2026-06-24T03:55:28.389146+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ironwood Q2 2022 GAAP net income $37M; LINZESS Rx demand up 9% YoY; guidance reiterated

## Summary
- GAAP net income of $37M ($0.21 diluted EPS); adjusted EBITDA of $56M; total revenue $97.2M, down 7% YoY.
- LINZESS EUTRx prescription demand grew 9% year-over-year in Q2 2022.
- Completed $75M share repurchase program and repaid remaining 2022 Convertible Notes in cash.
- Reiterated 2022 guidance: low single-digit % LINZESS net sales growth, total revenue $420-$430M, adjusted EBITDA >$250M.
- Phase 3 pediatric linaclotide study for functional constipation expected to readout in Q3 2022.

## SEC filing metadata
- accession: 0001104659-22-085865
- form_type: 8-K
- ticker: IRWD
- cik: 0001446847
- company_name: IRONWOOD PHARMACEUTICALS INC
- filed_at: 2022-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1446847/000110465922085865/0001104659-22-085865-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1446847/000110465922085865/tm2222410d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-085865
- JSON: https://secwatch.observer/filing/0001104659-22-085865.json
- Plain text: https://secwatch.observer/filing/0001104659-22-085865.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.